Notably, in the TCGA-BLCA cohort, EPHB6 expression was negatively correlated with the enrichment scores of most immunotherapy predicted pathways, such as IFN-γ signaling, DNA damage repair (DDR) signaling, cell cycle, and DNA replication related signaling (p<0.05; Figure 3D). Here, EPHB6 is linked to bladder transitional cell carcinoma.